Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Merit Medical Names Medtronic Veteran Martha Aronson As Next CEO, Projects Strong Outlook

Author: Nabaparna Bhattacharya | July 08, 2025 07:34am

Merit Medical Systems Inc. (NASDAQ:MMSI) announced a leadership transition on Monday, naming Martha Aronson as its next President and CEO, effective October 3, 2025.

Current CEO Fred Lampropoulos, who founded the company in 1987, will continue to serve as Chairman of the Board following the transition.

The Utah-based medical technology company also provided early revenue estimates for the second quarter, projecting between $380 million and $384 million in unaudited sales, a year-over-year rise of 12% to 14% compared to the same period in 2024. The analyst consensus estimate is pegged at $372.47 million. Constant currency growth is expected in the range of 11% to 13%.

Also Read: FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device Malfunction

Following the announcement, Needham analyst Mike Matson reiterated a buy rating for Merit Medical Systems and maintained a $108 price forecast.

In the first quarter of 2025, Merit Medical Systems delivered a strong performance, with revenue climbing to $355.4 million, up 9.8% from the same period last year. On a constant currency basis, organic growth reached 6%, signaling solid underlying demand across its portfolio.

Leadership Change Marks New Chapter

Aronson brings with her a wealth of experience in international healthcare management. She previously held executive roles at companies like Ecolab Inc. (NYSE:ECL) and Hill-Rom Holdings Inc., and spent nearly two decades in leadership positions at Medtronic plc. (NYSE:MDT).

She currently serves on the board of CONMED Corporation (NYSE:CNMD) and has held directorships at several other medical and tech firms. Lead Independent Director Dr. F. Ann Millner said the board was united in choosing Aronson after an exhaustive selection process.

Price Action: MMSI shares are trading higher by 2.12% to $93.05 premarket at last check Tuesday.

Read Next:

Photo by PeopleImages.com – Yuri A via Shutterstock

Posted In: CNMD ECL MDT MMSI

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist